137 related articles for article (PubMed ID: 38511583)
1. The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers.
Jodl SJ; Ten Voorde W; Klein S; Wagenfeld A; Zollmann FS; Feldmüller M; Klarenbeek NB; de Bruin DT; Jansen MAA; Rissmann R; Rohde B; Moerland M
Clin Transl Sci; 2024 Mar; 17(3):e13771. PubMed ID: 38511583
[TBL] [Abstract][Full Text] [Related]
2. Discovery of IRAK4 Inhibitors
Bothe U; Günther J; Nubbemeyer R; Siebeneicher H; Ring S; Bömer U; Peters M; Rausch A; Denner K; Himmel H; Sutter A; Terebesi I; Lange M; Wengner AM; Guimond N; Thaler T; Platzek J; Eberspächer U; Schäfer M; Steuber H; Zollner TM; Steinmeyer A; Schmidt N
J Med Chem; 2024 Jan; 67(2):1225-1242. PubMed ID: 38228402
[TBL] [Abstract][Full Text] [Related]
3. Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model.
Assil S; Buters TP; Hameeteman PW; Hallard C; Treijtel N; Niemeyer-Van der Kolk T; de Kam ML; Florencia EFIII; Prens EP; van Doorn MBA; Rissmann R; Klarenbeek NB; Jansen MAA; Moerland M
Front Immunol; 2023; 14():1197650. PubMed ID: 37545524
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers.
Buters TP; Hameeteman PW; Jansen IME; van Hindevoort FC; Ten Voorde W; Grievink HW; Schoonakker M; de Kam ML; Gilroy DW; Feiss G; Rissmann R; Jansen MAA; Burggraaf J; Moerland M
Clin Pharmacol Ther; 2022 Apr; 111(4):964-971. PubMed ID: 34935141
[TBL] [Abstract][Full Text] [Related]
5. Delayed ultraviolet erythema not suppressed by oral prednisolone: a randomized crossover study.
Muller FM; Dawe RS; Murdoch RD; McHugh SM; Marshall RP; Sousa A; Sanderson B; Ferguson J
Photodermatol Photoimmunol Photomed; 2009 Jun; 25(3):143-5. PubMed ID: 19438993
[TBL] [Abstract][Full Text] [Related]
6. IRAK4 kinase activity is not required for induction of endotoxin tolerance but contributes to TLR2-mediated tolerance.
Xiong Y; Pennini M; Vogel SN; Medvedev AE
J Leukoc Biol; 2013 Aug; 94(2):291-300. PubMed ID: 23695305
[TBL] [Abstract][Full Text] [Related]
7. Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers.
Buters TP; Hameeteman PW; Jansen IME; van Hindevoort FC; Ten Voorde W; Florencia E; Osse M; de Kam ML; Grievink HW; Schoonakker M; Patel AA; Yona S; Gilroy DW; Lubberts E; Damman J; Feiss G; Rissmann R; Jansen MAA; Burggraaf J; Moerland M
Br J Clin Pharmacol; 2022 Feb; 88(2):680-690. PubMed ID: 34293819
[TBL] [Abstract][Full Text] [Related]
8. Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation.
Shokrian Zeini M; Haddadi NS; Shayan M; Shokrian Zeini M; Kazemi K; Solaimanian S; Abdollahifar MA; Hedayatyanfard K; Dehpour AR
Int Immunopharmacol; 2021 Nov; 100():108160. PubMed ID: 34583123
[TBL] [Abstract][Full Text] [Related]
9. Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers.
Niemeyer-van der Kolk T; Assil S; Buters TP; Rijsbergen M; Klaassen ES; Feiss G; Florencia E; Prens EP; Burggraaf J; van Doorn MBA; Rissmann R; Moerland M
Clin Transl Sci; 2020 May; 13(3):573-579. PubMed ID: 32043302
[TBL] [Abstract][Full Text] [Related]
10. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
Bhujbal SP; He W; Hah JM
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
[TBL] [Abstract][Full Text] [Related]
11. Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity.
Dudhgaonkar S; Ranade S; Nagar J; Subramani S; Prasad DS; Karunanithi P; Srivastava R; Venkatesh K; Selvam S; Krishnamurthy P; Mariappan TT; Saxena A; Fan L; Stetsko DK; Holloway DA; Li X; Zhu J; Yang WP; Ruepp S; Nair S; Santella J; Duncia J; Hynes J; McIntyre KW; Carman JA
J Immunol; 2017 Feb; 198(3):1308-1319. PubMed ID: 28003376
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
[TBL] [Abstract][Full Text] [Related]
13. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
Lavazais S; Jargosch M; Dupont S; Labéguère F; Menet C; Jagerschmidt C; Ohm F; Kupcsik L; Parent I; Cottereaux C; Marsais F; Oste L; Van de Water A; Christophe T; De Vos S; Fallon P; Lauffer F; Clément-Lacroix P; Eyerich K; Brys R
Sci Transl Med; 2023 Feb; 15(683):eabj3289. PubMed ID: 36791209
[TBL] [Abstract][Full Text] [Related]
14. IRAK4 as a molecular target in the amelioration of innate immunity-related endotoxic shock and acute liver injury by chlorogenic acid.
Park SH; Baek SI; Yun J; Lee S; Yoon DY; Jung JK; Jung SH; Hwang BY; Hong JT; Han SB; Kim Y
J Immunol; 2015 Feb; 194(3):1122-30. PubMed ID: 25548221
[TBL] [Abstract][Full Text] [Related]
15. Impact of oral administration of single strain
Saghari M; Gal P; Grievink HW; Klaassen ES; Itano A; McHale D; Moerland M
Front Immunol; 2022; 13():1009304. PubMed ID: 36582231
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
Hao Y; Ma J; Wang J; Yu X; Li Z; Wu S; Tian S; Ma H; He S; Zhang X
Eur J Med Chem; 2023 Oct; 258():115616. PubMed ID: 37413880
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development.
van der Kolk T; Assil S; Rijneveld R; Klaassen ES; Feiss G; Florencia E; Prens EP; Burggraaf J; Moerland M; Rissmann R; van Doorn MBA
Clin Transl Sci; 2018 Nov; 11(6):607-615. PubMed ID: 29768709
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice.
Wang H; Zhou H; Zhang Q; Poulsen KL; Taylor V; McMullen MR; Czarnecki D; Dasarathy D; Yu M; Liao Y; Allende DS; Chen X; Hong L; Zhao J; Yang J; Nagy LE; Li X
J Hepatol; 2020 Dec; 73(6):1470-1481. PubMed ID: 32682051
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of IRAK1 and IRAK4 prevents endothelial inflammation and atherosclerosis in ApoE
Wu X; Xu M; Liu Z; Zhang Z; Liu Y; Luo S; Zheng X; Little PJ; Xu S; Weng J
Pharmacol Res; 2022 Jan; 175():106043. PubMed ID: 34954030
[TBL] [Abstract][Full Text] [Related]
20. A small molecule potent IRAK4 inhibitor abrogates lipopolysaccharide-induced macrophage inflammation in-vitro and in-vivo.
Choudhary SA; Patra D; Sinha A; Mazumder S; Pant R; Chouhan R; Jha AN; Prusty BM; Manna D; Das SK; Tikoo K; Pal D; Dasgupta S
Eur J Pharmacol; 2023 Apr; 944():175593. PubMed ID: 36804543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
